자궁경부암 세포주에서 cisplatin의 세포독성에미치는 glutathione 투여 시간의 효과
The Effects of Glutathione on Human Cancer Cells before and afterthe Application of Cisplatin
1
조회
0
다운로드
0
인용
0
참고문헌
초록
목적 : 이번 연구의 목적은 cisplatin에 의해 야기된 인간 자궁경부암 세포의 독성에 대한 glutathione의 시간에 따른 영향을 규명하기 위한 것이었다. 연구 방법 : 인간 자궁경부암세포 (SiHa: squamous cell carcinoma cell, CaSki: epidermoid metastatic carcinoma cell)는 RPMI1640 media에서 배양되었고 cisplatin (2-50 µM/ml 투여 1시간 전과 후에 환원된 glutathione (GSH) 또는 2-oxo 4-thiazolidine carboxylic acid (OTC)가 첨가되었다. 투여 후 세포들은 24시간 동안 배양되었고 살아있는 세포들은 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay를 이용하여 측정하였다. 결과 : Cisplatin으로 처치된 경부암 세포들의 MTT 환원율은 cisplatin 처치전과 후 모두다 glutathione (5 mM) 또는 OTC (5 mM)를 첨가했을 때 유의있게 증가하였다. GSH와 OTC를 투여했던 군에서 cisplatin 투여 1시간 전과 후에의 MTT 환원율의 차이는 관찰되지 않았다. 결론 : 이러한 결과로 볼 때 GSH와 OTC는 cisplatin에 의해 야기된 세포독성에 보호작용이 있으며 cisplatin 투여전과 후의 시간에 따른 차이는 없었다.
Abstract
Objective : The purpose of this study is to determine the time-dependant effects of Glutathione on the Cisplatin-induced cytotoxicity of human cervical carcinoma cells. Methods : Two human cervical carcinoma cells, SiHa (squamous cell carcinoma cell), and CaSki (epidermoid metastatic carcinoma cell) were cultivated with RPMI1640 media. Reduced glutathione (GSH) and 2-oxo 4-thiazolidine carboxylic acid (OTC) were added one hour before and after Cisplatin (2-50 µM/ml) was applied. The cells were incubated an additional 24 hours and viable cells were examined using a 3-[4,5- dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay. Results : The MTT reduction rate of cisplatin-treated cervical carcinoma cells was increased significantly by the addition of glutathione (5 mM) or OTC (5 mM) both one hour before and after Cisplatin. A difference between MTT reduction rates one hour before and after cisplatin were not observed in either GSH or OTC. Conclusion : These results suggest that GSH and OTC have a protective effect on cisplatin-induced toxicity, and that this effect is about the same whether the agents were applied before or after the Cisplatin.
참고문헌 (15)
- "a role in breast cancer treatment?", 28, pp.28~37 (2001)
- "Molecular mechanisms involved in cisplatin cytotoxicity", 57, pp.1229~1235 (2000)
- "Mechanisms of resistance to cisplatin", 478, pp.23~43 (2001)
- "Resistance to cisplatin", 14, pp.143~151 (1999)
- "Glutathione and glutathione delivery compounds", 38, pp.65~78 (1997)
- "Glutathione: an overview of biosynthesis and modulation", 24, pp.1~14 (1998)
- "Adverse effects of cytotoxics-platinum agents", 16, pp.171~97 (1997)
- "Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells", 31, pp.549~558 (1999)
- "Resistance to cisplatin", 14, pp.143~151 (1999)
- "Glutathione-related enzymes, glutathione and multidrug resistance", 12, pp.155~170 (1993)
- "Neoadjuvant chemotherapy in gynecologic oncology", 81, pp.965~985 (2001)
- "High dose chemotherapeutic strategies in the treatment of epithelial ovarian carcinoma", 11, pp.17~21 (1999)
- "An improved MTT assay", 157, pp.203~207 (1993)
- "Enhanced expression of gamma-glutamylcysteine synthetase and glutathione S-transferase genes in cisplatin-resistant bladder cancer cells with multidrug resistance phenotype", 157, pp.1054~1058 (1997)
- "Glutathione therapy:from prodrugs to genes", 18, pp.415~424 (1998)